Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 7, 2008

View Archived Issues

BMD increased by percutaneous injection of novel GEM-OS2 in preclinical studies

Bone formation enhanced with GSK's calcium-sensing receptor antagonist ronacaleret

New agents for diabetic nephropathy disclosed in recent Kowa patent

Recent Wyeth patent reports novel bazedoxifene prodrugs

AEterna completes enrollment in phase III study of LHRH antagonist cetrorelix in BPH

Boehringer and Evec sign license agreement for fully human therapeutic antibody program

Athera and Dyax sign collaboration agreement for antibodies in cardiovascular inflammation

Calabar initiates phase II study of Xalieve in xerostomia

AEterna initiates second stage of patient recruitment in phase II ovarian cancer trial of AEZS-108

Novel agents for cardiovascular disorders described in recent patent literature

deCODE files IND for DG-071 for Alzheimer's disease and other cognitive disorders

Genentech, Roche and Glycart sign development agreement for monoclonal antibody GA-101

Genentech reports case of PML in patient who received Raptiva for more than 4 years

Crucell receives contract from NIAID to advance Ebola and Marburg vaccines

DSMB recommends continuation of BioMS Medical's MAESTRO-03 trial of dirucotide in MS

Lilly and Deciphera sign agreement for B-Raf kinase inhibitors for cancer treatments

Astellas launches Irribow in Japan for diarrhea-predominant IBS

CombinatoRx reports top-line results from phase IIb Synavive study

Dendreon presents interim data from phase III Provenge trial

PDC Biotech reports progress on preclinical program for PDC-31

Rifaximin achieves significant results in prevention of hepatic encephalopathy

Unigene initiates phase I study for oral PTH

Lilly to acquire ImClone Systems

R&D highlights from the UBS Global Life Sciences Conference in New York: Vectura Group

Novel pharmacological chaperones identified as promising agents to treat phenylketonuria

Adjuvant therapy with catumaxomab safe in phase II gastric cancer study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...